NEW YORK (Reuters Health) May 30 –
The results of the Celecoxib Long-term Arthritis Safety Study (CLASS) trial leave the false impression that selective cyclooxygenase 2 (COX 2) inhibitors have fewer gastrointestinal side effects than nonsteroidal anti-inflammatory drugs (NSAIDs), researchers conclude in an article published in the June 1st issue of the British Medical Journal.
Dr. Peter J ni, from the University of Berne, Switzerland, and colleagues report that despite evidence of problems with the results from the CLASS trial, these results have been widely distributed
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!